Explore how nanotechnology is revolutionizing cancer immunotherapy through nanovaccines that train the immune system to fight cancer cells with precision.
Discover how graph neural networks and molecular docking are revolutionizing cancer immunotherapy by identifying potent PD-1/PD-L1 small molecule inhibitors.
Discover how FF-10101, a novel CSF1R inhibitor with unique covalent binding, reprograms tumor-associated macrophages to create an anti-tumor immune environment and enhances cancer immunotherapy.
Explore the groundbreaking Phase I trial of hu3S193, a humanized monoclonal antibody targeting Lewis-Y antigen in epithelial cancers. Learn about its precision targeting, pharmacokinetics, and future therapeutic potential.